Biden
Our work spans the major tissues implicated in whole body fuel use: the pancreatic beta-cells which make and secrete insulin in a co-ordinated response to food intake; skeletal muscle which is a key target of insulin and, as such, accounts for the bulk disposal of glucose following a meal; and liver, which releases glucose into the circulation and clears insulin from it. As diabetes can be viewed in terms of a failure, or aberrant regulation, of specific intracellular signalling pathways in one or more of these tissues, our groups are probing the signal transduction pathways that have relevance to the condition i.e. insulin secretion, glucose homeostasis and those that are lipid-responsive.
Staff
Dr James Cantley |
Dr Veronica Stevens |
Ebru Gurisik |
PhD Student James Burchfield |
| PhD Student Amanda Preston |
See also:
Schmitz Peiffer Research Group
News
Potential to prevent loss of insulin in Type 2 diabetes
MEDIA RELEASE:
14 Jul 2008
Until now, it was thought that the processes leading to the death of insulin-secreting pancreatic cells were similar in both types of diabetes. Scientists at Garvan have now shown that the process is quite different in the two diseases. They have also identified a promising therapeutic target for people with Type 2 diabetes
Solving a critical part of the insulin puzzle
MEDIA RELEASE:
04 Oct 2007
We are now one step closer to improved treatment of Type 2 diabetes following significant findings made by scientists at the Garvan Institute of Medical Research. The team from Garvan's Diabetes Signalling Unit, led by Associate Professor Trevor Biden and Dr Carsten Schmitz-Peiffer, has identified a very important biological target that will enable them to address one of the major underlying causes of diabetes.
